BioCentury
ARTICLE | Emerging Company Profile

Interception springboard

Provention takes the reins from Janssen on two autoimmune interception programs

September 29, 2017 11:28 PM UTC

Provention Bio Inc. is starting off with the benefit of experience gained at Johnson & Johnson’s Janssen Research & Development LLC unit, as well as disease interception assets generated in the pharma’s immunology group.

In June, the newco launched with a $28.4 million series A round from Johnson & Johnson Innovation-JJDC Inc. and JDRF T1D fund and three in-licensed assets, including two undisclosed autoimmune candidates from J&J. ...